-
Switch 2 sales boost Nintendo results but chip shortage looms
-
From rations to G20's doorstep: Poland savours economic 'miracle'
-
Russia resumes strikes on freezing Ukrainian capital
-
'Way too far': Latino Trump voters shocked by Minneapolis crackdown
-
England and Brook seek redemption at T20 World Cup
-
Coach Gambhir under pressure as India aim for back-to-back T20 triumphs
-
'Helmets off': NFL stars open up as Super Bowl circus begins
-
Japan coach Jones says 'fair' World Cup schedule helps small teams
-
Equities and precious metals rebound after Asia-wide rout
-
Do not write Ireland off as a rugby force, says ex-prop Ross
-
Winter Olympics 2026: AFP guide to Alpine Skiing races
-
Winter Olympics to showcase Italian venues and global tensions
-
Buoyant England eager to end Franco-Irish grip on Six Nations
-
China to ban hidden car door handles in industry shift
-
Sengun leads Rockets past Pacers, Ball leads Hornets fightback
-
Waymo raises $16 bn to fuel global robotaxi expansion
-
Netflix to livestream BTS comeback concert in K-pop mega event
-
Rural India powers global AI models
-
US House to vote Tuesday to end shutdown
-
Equities, metals, oil rebound after Asia-wide rout
-
Bencic, Svitolina make history as mothers inside tennis top 10
-
Italy's spread-out Olympics face transport challenge
-
Son of Norway crown princess stands trial for multiple rapes
-
Side hustle: Part-time refs take charge of Super Bowl
-
Paying for a selfie: Rome starts charging for Trevi Fountain
-
Faced with Trump, Pope Leo opts for indirect diplomacy
-
NFL chief expects Bad Bunny to unite Super Bowl audience
-
Australia's Hazlewood to miss start of T20 World Cup
-
Bill, Hillary Clinton to testify in US House Epstein probe
-
Cuba confirms 'communications' with US, but says no negotiations yet
-
Iran orders talks with US as Trump warns of 'bad things' if no deal reached
-
From 'watch his ass' to White House talks for Trump and Petro
-
Liverpool seal Jacquet deal, Palace sign Strand Larsen on deadline day
-
Trump says not 'ripping' down Kennedy Center -- much
-
Sunderland rout 'childish' Burnley
-
Musk merges xAI into SpaceX in bid to build space data centers
-
Former France striker Benzema switches Saudi clubs
-
Sunderland rout hapless Burnley
-
Costa Rican president-elect looks to Bukele for help against crime
-
Hosts Australia to open Rugby World Cup against Hong Kong
-
New York records 13 cold-related deaths since late January
-
In post-Maduro Venezuela, pro- and anti-government workers march for better pay
-
Romero slams 'disgraceful' Spurs squad depth
-
Trump urges 'no changes' to bill to end shutdown
-
Trump says India, US strike trade deal
-
Cuban tourism in crisis; visitors repelled by fuel, power shortages
-
Liverpool set for Jacquet deal, Palace sign Strand Larsen on deadline day
-
FIFA president Infantino defends giving peace prize to Trump
-
Trump cuts India tariffs, says Modi will stop buying Russian oil
-
Borthwick backs Itoje to get 'big roar' off the bench against Wales
US House votes for life-changing $35 insulin price cap
US lawmakers voted Thursday on a bill limiting the cost of insulin to $35 a month, a transformative curb for millions of diabetics who pay hundreds of dollars for the life-sustaining hormone.
Drug pricing has vexed politicians for years in the United States, which has the highest annual health expenditure of any industrialized country, at around $11,000 per capita.
Insulin costs the 7.4 million American adults who use it to manage their diabetes eight times as much as in other wealthy nations, according to a 2020 study commissioned by the Health and Human Services Department.
"This is a kitchen table issue: are people going to be able to pay their bills? And it is, for us, a step in the direction of the (government) being able to negotiate for lower drug prices beyond insulin," House Speaker Nancy Pelosi told reporters.
The legislation passed the House of Representatives by 232 votes to 193, with a handful of Republicans crossing the aisle to join the Democrats, and now advances to the upper chamber of Congress, the US Senate.
It would require private health insurance companies to set prices for a month's supply of insulin at no more than $35, or 25 percent of a plan's negotiated price, whichever is lower, starting in 2023 for some patients and 2024 for all.
The cap was a provision in President Joe Biden's "Build Back Better" social welfare bill that was torpedoed by Democratic infighting in Congress late last year.
Biden brought the issue back into the spotlight during his State of the Union address on March 1, reinvigorating calls for action on pricing from diabetes advocates.
The effort is being seen as the only way for Democrats to show they're capable of acting on sky-high prescription drug prices before November's midterm elections.
- 'Costing a lot' -
The Senate is holding its own cross-party negotiations on driving down insulin costs by targeting the middlemen between health insurance companies and pharmacies.
And a separate Democrat-only bill from Georgia's Senator Raphael Warnock that would also cap the price at $35 is likely to be combined with the effort.
"I'm a pastor -- I'm on the ground -- and so I know that everybody knows somebody with diabetes," Warnock said in a video promoting his initiative.
Senate Majority Leader Chuck Schumer told reporters last week he believed a bipartisan bill had a good chance of passing when lawmakers return from a break at the end of April.
Research suggests that more than a quarter of Americans with type 1 diabetes have had to ration insulin they could not afford. Campaigners say the proportion went up to 50 percent during the pandemic.
It remains unclear if any legislation can gain the 10 Republican votes needed to advance in the Senate, but some opposition lawmakers have shown interest in an issue that affects voters across the board.
"I'd be for some kind of regulation where we can help. Too many people (are) paying thousands of dollars a month. I'm not big on regulating process, but that one's costing a lot of people a lot of money," Alabama Senator Tommy Tuberville told Axios.
Republicans on the powerful House Ways and Means Committee described the vote as "the largest expansion of federal command and control in Americans' private health insurance design" since the Affordable Care Act, the landmark 2010 regulatory overhaul and expansion of health care coverage.
"Democrats are reviving their socialist drug pricing scheme from their failed radical tax and spending spree," the committee's top Republican Kevin Brady said in a statement.
J.Bergmann--BTB